How The Story For Johnson & Johnson (JNJ) Is Shifting With New Drugs And Legal Twists

The intrinsic value estimate for Johnson & Johnson has shifted slightly, with the fair value moving from US$252.42 to ...
Fierce Pharma

AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard

After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the ...
Healio

Tremfya nabs FDA approval for active ulcerative colitis, chasing competitor Skyrizi

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...
WebMD

Managing Ulcerative Colitis With Tremfya

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
Medindia

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

TREMFYA® is approved Europe, Canada, Japan, and a number of other countries for the treatment of adults with moderate-to-severe plaque psoriasis and for the treatment of adults with active psoriatic ...
Healio

VIDEO: Tremfya induces increased rates of clinical remission in Crohn’s

Please provide your email address to receive an email when new articles are posted on . In a video exclusive, Jan Wehkamp, MD, vice president, gastroenterology global disease area leader at Janssen ...
FiercePharma

Johnson & Johnson’s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown

Johnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data. At the 48-week mark, 84.5% of ...
Monthly Prescribing Reference

Tremfya Approved for Moderately to Severely Active Ulcerative Colitis

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...
Monthly Prescribing Reference

Tremfya Approved for Moderate to Severe Plaque Psoriasis

In the NAVIGATE study, 31% of patients treated with Tremfya were considered cleared or almost cleared vs. 14% of patients treated with Stelara (ustekinumab; Janssen Biotech) at Week 28. Janssen ...